Publications, Pharmaceutical

Developing in vitro dissolution tests for orally inhaled drug products

The fate of inhaled drug substances, in vivo, is not well-understood but is believed to be dependent, to some extent, on dissolution characteristics.

This paper presents work to develop an in vitro apparatus and standardized methodology for quantifying the dissolution behavior of orally inhaled drug products. The developed solution incorporates an aerosol dose collection apparatus that collects the dose over a large area, and a modified USP Apparatus V Paddle Over Disc for dissolution testing. The discriminating ability of this solution was demonstrated via testing with a range of commercially available orally inhaled drug products (MDIs and DPIs). Good correlation was observed between in vivo mean absorption time and in vitro dissolution half-life. It is concluded that the developed solution has potential for compendial and QC testing and in the development of both branded and generic orally inhaled drug products.

Download Publication
10 Jun 2020

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

25 Jun 2020

Confirming bioequivalence for a generic tiotropium dry powder inhalers

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
25 Jun 2020

Comparison of Pulmonary Deposition for Single and Multidose Dry Powder Inhalers with ...

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations

Read More
15 Jun 2020

Accelerating the development of COVID vaccines and therapeutics

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
15 Jun 2020

Evaluating the Particle Distribution for Dry Powder Inhalers

Publications, Pharmaceutical, Brand Differentiation, Product Solutions, Innovation & Insights

Read More
1 13 14 15 16 17 19
Back To Top